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JAMIE L. EBERLING, PH.D., AND WILLIAM J. JAGUST, M.D. 
Neurodegenerative diseases such as Alzheimer’s disease, disorders such as alcoholism, and the 
aging process can lead to impaired cognitive function and dementia. Researchers and clinicians 
have used noninvasive imaging techniques to determine the structural and physiological 
alterations in the brain that are associated with these conditions. Analyses of the brain’s 
structure have found that shrinkage (atrophy) of the brain tissue is characteristic for all 
conditions associated with dementia, but that the specific locations of atrophied brain structures 
vary among different neurodegenerative diseases and alcohol­induced disorders. Similarly, 
studies analyzing the metabolism in various brain structures have found that, depending on 
whether dementia was induced by neurodegenerative diseases, alcoholism, or aging, the 
affected brain structures vary slightly. Based on such studies, researchers and clinicians now 
can more accurately define different types of dementia and predict their clinical course. KEY 
WORDS: neuroimaging; aging; dementia; brain atrophy; CNS degenerative disorder; Alzheimer’s disease; 
computed x­ray tomography; magnetic resonance imaging; positron emission tomography; single photon 
emission computed tomography; Parkinson’s disease; Korsakoff’s syndrome 
Neurodegenerative diseases such as these techniques, see the article by Doria, eases. Comparatively less research has an­Alzheimer’s disease (AD) (see pp. 261–265.) alyzed how chronic alcohol use affectssidebar, p. 280), disorders such as Brain imaging techniques have both brain structure and physiology and how
alcoholism, and even the normal aging pro­ clinical and research applications. Clini­ these effects correlate with cognitive de­
cess can severely impair a person’s cognitive cians use imaging technology as a diagnostic ficits observed in alcoholics. However,
tool to distinguish between different types studies of the effects of aging may be re­functioning. These cognitive disturbances
of dementia1 (e.g., dementia due to AD or levant to alcohol research because several frequently are accompanied by structural
alcoholism), allowing them to more accu­ researchers have postulated that alcohol­and physiological changes in the brain. Con­
rately determine the patient’s prognosis, ism may accelerate normal aging pro­
siderable advances in brain imaging tech­ prescribe appropriate therapy, and provide cesses or induce premature aging of the 
nology have provided researchers and
adequate counseling. Researchers, on the
clinicians with new tools to study these
other hand, can use brain imaging to inves­
changes and relate them to cognitive dis­ JAMIE L. EBERLING, PH.D., is a stafftigate pathological metabolic changes asso­
turbances. Among the most commonly scientist at the Center for Functional ciated with natural aging processes and with
used techniques are computed tomography age­related or neurodegenerative diseases. Imaging, Lawrence Berkeley NationalLaboratory, Berkeley, California. (CT) and magnetic resonance imaging This article summarizes some of the find­
(MRI), which allow evaluation of the brain ings of such analyses, which have focused WILLIAM J. JAGUST, M.D., is head of the
structure. Single­photon emission computed mainly on the effects of aging and on de­ Neuroscience Group at the Center for
tomography (SPECT) and positron emission mentia caused by neurodegenerative dis­ Functional Imaging, Lawrence Berkeley
tomography (PET) allow researchers to National Laboratory, Berkeley, and a
visualize brain functioning (e.g., the rate professor in the Department of Neurology,1For a definition of this and other technical terms see the 
of metabolism). (For more information on central glossary, pp. 293–295. University of California, Davis, California. 
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DEMENTIA AND ITS CAUSES
 
The term “dementia” denotes any con­
dition characterized by severe global
intellectual impairment, including loss
of memory functions and abstract think­
ing, personality changes, disruption of
social skills, and other impairments of
higher brain functions. Dementia can
have a variety of causes, including
alcoholism and other drug abuse, neu­
rodegenerative diseases, and brain
injuries or tumors. 
Alcoholism 
Alcoholism can lead to several degrees
of cognitive dysfunction and pathologi­
cal changes in the brain structure. Most
commonly, chronic alcohol abuse is
associated with relatively subtle cogni­
tive and motor deficits (Martin et al.
1986). More rarely, alcoholism leads to
alcoholic dementia, a neurobehavioral
syndrome marked by a global loss of
intelligence. In contrast, alcoholics with
Korsakoff’s syndrome (KS) exhibit a
more specific memory dysfunction
marked by a permanent inability to re­
member new facts and events for more 
than a few seconds (i.e., anterograde
amnesia) as well as deficits in nonmem­
ory realms, such as temporal discrimina­
tion, spatial organization, abstraction, and
initiative (Squire 1982). In addition to
the severe deficits that define alcoholic 
dementia and KS, both conditions in­
clude the milder dysfunctions associated
with chronic alcoholism. 
Neurodegenerative Diseases 
Neurodegenerative diseases (i.e., diseases
in which parts of the nervous system are
progressively destroyed) potentially result­
ing in dementia include Alzheimer’s dis­
ease (AD), Huntington’s disease (HD), and
Parkinson’s disease (PD). AD, which oc­
curs mainly in people over age 65 and is the
most common cause of dementia, is char­
acterized by progressive cognitive and
intellectual deterioration (e.g., confusion,
memory failure, and disorientation). These
symptoms are accompanied by pathologi­
cal changes in the brain, such as the de­
generation of nerve fibers in certain brain
regions (i.e., neurofibrillary tangles) and
the formation of protein aggregates (i.e.,
senile plaques) in the brain tissue. HD is
an inherited disease that usually develops
during middle age. It is characterized by
mental deterioration and involuntary, pur­
poseless, rapid movements (e.g., flexing
and extending the fingers or grimacing).
PD, which primarily develops in people
over age 60, is characterized mainly by
rapid shaking of certain muscles (i.e.,
tremors) and a shuffling gait. Not all PD
patients, however, show mental deteriora­
tion. Pathological changes in the brains of
PD patients include the destruction of nerve
cells in certain brain regions (e.g., the basal 
ganglia) and depletion of the neuro­
transmitter dopamine in brain struc­
tures that normally contain high
dopamine levels (e.g., the striatum). 
Brain Injury 
After AD, ischemic infarcts in the brain,
also called ischemic strokes, are the
most common cause of dementia. The 
term “stroke” applies to all conditions
during which the blood supply to a
brain region is interrupted, leading to
the death of surrounding brain tissue.
During an ischemic infarct the blood
flow is interrupted by a block in one of
the blood vessels. The resulting condi­
tion of cognitive deterioration is called
ischemic vascular dementia. The second 
type of stroke is the hemorrhagic stroke,
which is caused by bleeding within the
brain due to a ruptured blood vessel.
—Jamie L. Eberling
and William J. Jagust 
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brain (For a review, see Evert and Oscar­
Berman 1995). 
STRUCTURAL BRAIN ANALYSES 
CT Studies of AD Patients 
Both CT and MRI allow researchers to 
analyze brain structure and therefore can
help detect abnormalities in the brain that
may cause dementia, such as large lesions,
damaged blood vessels, structural asym­
metries, and abnormalities of the ventricles
(i.e., cavities in the brain that are filled with
cerebrospinal fluid [CSF]). CT particularly
is useful in evaluating dementia resulting
from large cortical infarcts (i.e., regions in
which brain tissue dies because the blood 
supply is interrupted) but is less suitable for
evaluating dementing diseases. For example,
AD and ischemic vascular dementia (IVD)
(see sidebar), in which the structural dam­
age is more subtle, are not readily detectable
using CT. Moreover, CT cannot identify
some lesions because of its low contrast 
sensitivity (i.e., the signals of diseased and
normal tissues are similar on the image).
Nevertheless, CT often is used to rule out
potentially reversible causes of dementia,
such as tumors and other types of structural
abnormalities that CT can detect easily.
Despite the technology’s limitations, CT
studies of AD patients have demonstrated
that the primary structural changes associ­
ated with the disease are shrinkage (i.e.,
atrophy) of the cerebral cortex and enlarge­
ment of the ventricles. The rate at which the 
volume of gray matter2 in the cortex de­
creases and the volume of CSF in the ven­
tricles and in the fissures on the brain’s 
surface (i.e., sulci) increases determines
the rate at which dementia progresses in
AD patients (Luxenberg et al. 1987). Gen­
eralized cortical atrophy and ventricular
enlargement, however, also occur in other
types of dementia (e.g., IVD) as well as in
normal aging; to distinguish AD from these
conditions, physicians must analyze the ex­
tent of atrophy in specific regions of the cor­
tex. For example, regional atrophy in the
temporal lobe3 can accurately distinguish 
2The gray matter of the brain mainly is composed of
the bodies of the nerve cells, whereas the white mat­
ter primarily is made up of the cells’ long extensions, 
or axons. 
3For the location of this and other brain structures,
see the figures on pp. 293–295. 
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the effects of AD from those of normal 
aging (Kido et al. 1989). Alternatively, a
physician could take several CT measure­
ments over a period of time to document
the rate of ventricular enlargement; more
rapid changes in ventricle size indicate
AD and distinguish it from slower, normal
aging processes. Both of these types of CT
measurements are fairly labor intensive
and expensive, however, and therefore are
not used routinely in the diagnosis of AD. 
CT Studies of Alcoholic Patients 
To better understand the effects of chronic 
alcohol consumption on the brain, neuro­
imaging studies have attempted to relate
structural brain alterations to clinical and 
cognitive changes associated with alco­
holism, just as changes in the brains of
AD patients have been related to those
patients’ cognitive deficits. Several CT
studies have demonstrated cortical atrophy
and ventricular enlargement in alcoholic
patients and reported relationships between
structural changes and specific cognitive
impairments. For example, Shimamura and
colleagues (1988) reported atrophy of the
frontal lobe and of an area near the Sylvian
fissure (i.e., a fissure on the brain surface
that separates the frontal lobe from the
temporal lobe) both in alcoholics with
Korsakoff’s syndrome (KS) (see sidebar)
and in nondemented alcoholics. In addition,
KS patients showed evidence of tissue loss
in regions other than the cortex (i.e., sub­
cortical regions), such as the thalamus, and
of increased volume of the third ventricle,
which is located in the center of the brain,
near the thalamus. The degree of frontal
lobe atrophy and tissue loss in the thalamus
correlated with the KS patients’ perfor­
mance on memory tests.
Alcohol’s effects on brain structure 
also may depend on the drinker’s age.
When alcoholics were compared with age­
matched nonalcoholics, increases in CSF
volume—which reflect a loss of brain 
tissue—in the alcoholics appeared to be
greater in older subjects than in younger
subjects (Pfefferbaum et al. 1993; also see
the article by Rosenbloom et al., pp. 266–
272). These findings suggest that the aging
brain may be increasingly vulnerable to the
effects of alcohol. Other research has indi­
cated that some of the alcohol­related struc­
tural changes may be partially reversible
with abstinence (Carlen et al. 1978). 
MRI Studies of Aging and Dementia 
MRI provides structural brain images that
are superior to CT in several ways. For
example, the contrast is greater in MRI
images than in those produced using CT,
allowing better distinction between gray
and white matter, improved identification
of white­matter lesions and subcortical 
infarcts, and more accurate volume deter­
mination of subcortical gray­matter struc­
tures (e.g., the thalamus). MRI also can
distinguish better between adjacent struc­
tures (i.e., has better spatial resolution)
than CT. Moreover, in contrast to CT,
MRI generates three­dimensional data
sets that can produce images of any struc­
ture from any angle. 
Some of the alcohol­
related structural 
changes may be
partially reversible
with abstinence. 
Because of their excellent contrast,
MRI images can, for example, detect
changes in the white matter near the ventri­
cles; these alterations often occur in AD and
IVD patients (and, to a lesser extent, dur­
ing normal aging) and may be associated
with specific cognitive deficits. In addition,
physicians can use MRI to distinguish IVD,
which is characterized by small white­matter
lesions that often are not visible on CT 
scans, from AD and thus improve the pa­
tient’s diagnosis and treatment. Although
MRI is useful to researchers for identify­
ing structural damage (e.g., white­matter
changes) in patients with dementia, the
clinical, diagnostic value of these observa­
tions often is limited and must be comple­
mented by a thorough clinical evaluation.
For example, the presence of white­matter
lesions does not preclude a diagnosis of
AD. In fact, using MRI, Harrel and col­
leagues (1987) observed white­matter
lesions in 36 percent of AD patients
studied. This finding could reflect either a
coexistence of AD and IVD in many pa­
tients or the nonspecific nature of white
matter changes.
The high spatial resolution of MRI
images also allows researchers to deter­
mine the size (i.e., volume) of small brain
structures (e.g., the hippocampus and the
amygdala) that are known to be affected in 
AD patients. For example, hippocampal
atrophy can distinguish AD patients from
age­matched control subjects (Seab et al.
1988; Jack et al. 1992) and thus assist in
the diagnosis of AD. Moreover, Golomb
and colleagues (1993) used MRI measure­
ments to demonstrate that hippocampal
atrophy even distinguishes subjects with
mild age­related memory impairments from
control subjects. The researchers also sug­
gested that hippocampal atrophy may pre­
dict future cognitive decline. 
MRI Studies of Alcoholic Patients 
Like CT studies, MRI analyses can detect
cerebral atrophy in chronic alcoholics. The
observed changes include increases in the
CSF volume as well as decreases in the 
volume of gray­matter structures (e.g., part
of the temporal lobe and of the hippocam­
pus) and white­matter structures (Jernigan
et al. 1991; Pfefferbaum et al. 1992; Shear
et al. 1994; Sullivan et al. 1995). Some of
the observed structural changes may corre­
late with the subjects’ cognitive functioning
as assessed by neuropsychological meas­
ures. For example, MRI studies of KS pa­
tients revealed more extensive nerve cell 
loss in the diencephalon (a brain region
beneath the cortex that includes the thala­
mus and hypothalamus) than in alcoholics
without the syndrome (Jernigan et al. 1991).
Other studies of chronic alcoholics have 
reported a correlation between impaired
neuropsychological functioning and in­
creased CSF volume in the ventricles and 
sulci, although no consistent relationships
have been found to exist between cognitive
measures and the volumes of specific corti­
cal or subcortical gray­matter structures
(Jernigan et al. 1991). The researchers sug­
gest that this apparent discrepancy may be
due, at least in part, to the considerable
variability among individuals in the vol­
umes of gray matter structures. Moreover,
most neuropsychological tests require the
function of multiple brain systems, making
correlations between test scores and a 
single brain structure less likely. 
FUNCTIONAL IMAGING 
Structural imaging approaches detect
changes in brain structure but allow no
conclusion as to whether these changes
actually affect brain function. In contrast,
functional imaging technologies, such as
PET and SPECT, permit the visualization
of brain functions by measuring variables
such as cerebral metabolism of glucose and 
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oxygen or regional cerebral blood flow
(RCBF). These techniques are based on
the observation that brain regions with
increased nerve cell activity show in­
creased blood flow and use more nutrients 
(e.g., oxygen and glucose) than inactive
brain regions. Studies using these tech­
niques usually compare brain functions
between patient groups (e.g., AD patients
or alcoholics) and normal control sub­
jects. In addition, both PET and SPECT
offer the opportunity to study components
of the chemical systems involved in signal
transmission within the brain (see box).
Both PET and SPECT use molecules 
labeled with a radioisotope (i.e., radioactive
tracers) to study the rates of blood flow and
various metabolic processes in the brain.
Tracers used for PET usually are radioactive
variants of physiological molecules; for ex­
ample, glucose molecules containing radio­
active fluoride are used to study glucose
metabolism, and water or oxygen molecules
containing radioactive oxygen atoms are
used to study RCBF or oxygen metabol­
ism. Tracer molecules for SPECT usually
are nonphysiological radioactive sub­
stances. The tracers can be injected into
the subject’s bloodstream or, in the case of
oxygen metabolism, inhaled. Computers
convert the data on the distribution of the 
radioactive tracers in the subject’s brain
into images. (For more information on
PET and SPECT, see the article by Doria,
pp. 261–265.)
Although compared with SPECT, PET
images show greater detail and more ac­
curately quantify the processes studied,
clinicians and researchers frequently prefer
SPECT because it is less costly, more widely
available, less technically challenging, and
uses tracers that are routinely available in
clinical nuclear medicine departments.
However, both PET and SPECT data can be
distorted by the atrophy that occurs in nor­
mal and pathological aging processes. The
shrinkage of brain tissue in a certain brain
region artificially lowers the overall meta­
bolic rate in that region because fewer cells
are available to metabolize glucose or oxy­
gen while simultaneously the amounts of
CSF and white matter are increased. Thus,
the images may indicate reduced meta­
bolism even when the metabolic rate in the 
remaining cells is normal. This limitation
has received more attention in PET than in 
SPECT studies, because PET is more fre­
quently used for quantitative analyses.
Several researchers have attempted to
develop correction factors to compensate
for effects of atrophy when calculating
metabolic rates (Chawluk et al. 1987, 1990; 
NEW APPLICATIONS OF PET AND SPECT 
Both positron emission tomography (PET) and single­photon emission computed
tomography (SPECT) allow scientists not only to measure physiological variables,
such as blood flow in the brain, but also to study various neurochemical systems.
For example, tracers exist that can help analyze the distribution of cellular compo­
nents, such as the docking molecules (i.e., receptors) on the brain cell surfaces to
which the molecules mediating nerve­signal transmission (i.e., neurotransmitters)
attach. Tracers are available that allow researchers to examine brain structures 
using the neurotransmitters dopamine and serotonin.
Neurochemical studies are potentially useful for diagnosing dementia associ­
ated with defects in cells that use a specific neurotransmitter system—for example,
Parkinson’s disease (PD), a neurodegenerative disorder primarily affecting cells
using dopamine. In addition, neurochemical studies enable researchers to examine
the relationship between specific neurochemical changes and disease symptoms
(e.g., how changes in the dopamine system relate to the motor symptoms [i.e.,
tremors] that occur in PD patients). Similar studies assess the response of various
neurotransmitter systems to pharmacological interventions. To date, these types
of studies have not been performed in alcohol research. 
Marchal et al. 1992), with contradictory
results. Technical advances in PET technol­
ogy, however, should reduce the influence
of atrophy and thus minimize this problem
in the future. 
PET and SPECT Studies of 
Neurodegenerative Diseases
and Aging 
PET and SPECT both have been used 
extensively to study AD and other neuro­
degenerative disorders and to relate the
physiological changes to cognitive and
clinical findings. The observed patterns
of changes in blood flow and brain meta­
bolism allow scientists and clinicians to 
distinguish between these disorders and
the normal aging process. 
Alzheimer’s Disease. PET studies consis­
tently have shown characteristic patterns
of blood flow and metabolism that are use­
ful for understanding the progression and
pathophysiology4 of AD as well as the rela­
tionship between cognitive deficits and
neurophysiological measurements. The
predominant finding is a decrease in RCBF,
glucose metabolism, and oxygen meta­
bolism in the temporal and parietal lobes,
with increasing involvement of other brain
regions—especially the frontal lobes—as
the disease progresses (figure 1). These lo­
calized decreases in blood flow and metabol­
ism correspond to the regional distribution
of nerve cell damage in AD (Friedland et
al. 1985). Studies examining the relation­
ship between glucose metabolism and 
4Pathophysiology is the study of the processes in the body 
that lead to the signs and symptoms of a disease. 
neuropathological markers of AD (i.e.,
neurofibrillary tangles and senile plaques
[see sidebar]) in more detail found that
glucose metabolism was low in areas with
a high density of neurofibrillary tangles
but did not correlate with the distribution 
of senile plaques (DeCarli et al. 1992).
Similarly, the presence of neurofibrillary
tangles, but not senile plaques, also corre­
lated with dementia severity (Arriagada et
al. 1992). SPECT studies using blood flow
tracers confirmed the pattern of reduced
metabolism in the parietal and temporal
lobes observed with PET (figure 2) and
established a correlation between the 
degree of RCBF reduction in these struc­
tures and the severity of the patients’
dementia (Jagust et al. 1987).
Several studies found that regional
cerebral metabolism and blood flow re­
ductions were associated with declines in 
specific cognitive functions attributed to
those regions. For example, AD patients
with predominant visuospatial deficits5 
had greater metabolic reductions in the
right half (i.e., hemisphere) of the brain,
whereas patients with predominant lan­
guage deficits had greater metabolic re­
ductions in the left hemisphere (Foster et al.
1983). Similarly, SPECT studies demon­
strated a relationship between the pattern
of RCBF changes and specific cognitive
deficits (Eberling et al. 1993). Thus, where­
as generally reduced metabolism in the
parietal and temporal lobes is typical of AD
patients, the specific patterns of affected
brain regions can differ significantly among 
5Visuospatial functions include reading maps, solving 
jigsaw puzzles, and performing motor skills involving 
spatial perception. 
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patients, contributing to the heterogeneity
in the patients’ clinical presentation. 
Huntington’s Disease and IVD. PET has 
been reasonably accurate in separating AD
patients from patients with other types of
dementia (e.g., Huntington’s disease (HD)
and IVD) as well as from normal control
subjects (table 1). For example, in contrast
to the reduced metabolism in the temporal
and parietal lobes that is characteristic of 
AD, PET studies of HD patients mainly de­
tected reduced metabolism in a subcortical 
structure called the caudate nucleus (Grafton
et al. 1992). IVD, by contrast, does not ap­
pear to be characterized by any single meta­
bolic pattern. SPECT studies of IVD also
found no single characteristic RCBF pat­
tern, but variously detected blood flow
deficits in regions of the temporal, parietal,
or frontal lobes as well as patchy global 
deficits (Eberling et al. 1992; Jagust et al.
1987; Komatani et al. 1988). This variabil­
ity probably is due to the fact that blood
flow interruptions in IVD can occur any­
where in the brain: Some patients show
signs of infarcts distributed diffusely
throughout subcortical structures, whereas
others have more localized lesions in the 
cortex. Moreover, IVD patients frequently
also suffer from AD and thus may exhibit
changes typical for both disorders. 
Parkinson’s Disease. PET studies of 
Parkinson’s disease (PD) patients found
that, as with AD, PD patients often show
decreased metabolism in the temporal and
parietal lobes (Peppard et al. 1992; Eber­
ling et al. 1994), possibly because some
PD patients also may have AD or preclini­
cal AD. This is supported by findings that
whereas PD patients both with and without
dementia show global metabolic reductions,
some demented PD patients (i.e., those
most likely also to have AD) show more
profound metabolic deficits in the parietal
and temporal lobes than nondemented PD
patients (Peppard et al. 1992). PD patients
also show metabolic deficits in areas of the 
occipital lobe that generally are unaffected
in AD (Eberling et al. 1994).
PET studies also found that PD patients
exhibited altered metabolism not only in
the cortex but also in subcortical structures. 
These findings included increased blood
flow and metabolism in the basal ganglia
(Rougemont et al. 1984) as well as reduced
metabolism of the neurotransmitter dopa­
mine in the striatum (Leenders et al. 1986),
which reflects the dopamine depletion
characteristic for this disease (see sidebar).
SPECT studies of PD patients revealed
reduced blood flow to the temporal and
parietal lobes (figure 2). For example,
Pizzolato and colleagues (1988) found de­
creased parietal RCBF in PD patients with
and without dementia, with the degree of
RCBF reduction reflecting the extent of
mental deterioration. Jagust and colleagues
(1992) also reported decreased RCBF in
the temporal lobe compared with control
subjects. These researchers were able to
establish an association of certain RCBF 
patterns with specific cognitive deficits in
the PD patients: Whereas reduced temporal
and parietal RCBF was related to the pa­
tients’ global cognitive performance, de­
creased RCBF in the frontal lobe correlated 
with more specific cognitive deficits com­
pared with control subjects, even in the
absence of dementia. 
Aging. PET studies of normal aging have
led to controversial findings concerning
age­related changes in cerebral glucose 
Figure 1 Positron emission tomography images from an Alzheimer’s disease (AD) 
patient (left) and a control subject (right). These images were taken at a 
level passing through the middle of the temporal lobe and hippocampus. 
The AD patient showed reduced metabolism in the temporal cortex and 
hippocampus. 
Table 1 Comparison of the Changes in Brain Metabolism Associated With 
Neurodegenerative Diseases, Alcoholism, and Aging. 
Condition Affected Brain Regions 
Alzheimer’s disease Reduced metabolism in the temporal lobes and parietal lobes 
Huntington’s disease Reduced metabolism in the caudate nucleus 
Parkinson’s disease Reduced metabolism in the temporal and parietal lobes, 
particularly in patients with cognitive decline 
Increased blood flow and metabolism in the basal ganglia 
(observed only in some studies) 
Normal aging Reduced metabolism in the temporal lobe but to a lesser 
extent than in Alzheimer’s disease 
Chronic alcoholism Reduced metabolism in several brain regions, particularly in 
the mesial frontal lobe 
Korsakoff’s syndrome Reduced metabolism in the frontal, parietal, and cingulate lobes 
metabolism, with different studies vari­
ously reporting global changes, more lo­
calized decreases, or no age­related changes
at all (Eberling et al. 1995). These conflict­
ing findings may stem partly from differ­
ences in subject selection, with some studies
selecting only subjects who are optimally
healthy (i.e., they do not suffer from dis­
eases typically associated with aging, such
as diabetes or heart disease) and others
applying less stringent criteria. Eberling
and colleagues (1995) studied a group of
optimally healthy older subjects who had
no cognitive deficits. The study found de­
creased temporal lobe metabolism, with
the greatest metabolic deficits in brain
regions that mediate widespread recipro­
cal connections between the temporal and
frontal lobes and structures of the limbic 
system; these regions probably play a role
in multiple cognitive functions, including
memories, and frequently show age­related
pathological changes. In general, the meta­
bolic patterns in these healthy subjects
were similar to those seen in AD patients
but with much less extensive deficits. It 
also is possible that some of the subjects
had preclinical AD; a previous study
showed that metabolic deficits character­
istic of AD may occur prior to the cogni­
tive deficits associated with the disease 
(Haxby et al. 1986). 
PET and SPECT Studies 
of Alcoholism 
Based on the effectiveness of functional 
imaging in monitoring the physiological
consequences of neurodegenerative dis­
eases and aging, researchers also have be­
gun using these techniques to study the
effects of alcohol and other drugs on the
brain. Several reports have assessed the 
effects of cocaine (Holman et al. 1992,
1993), but few PET and SPECT studies
have evaluated the neuropathological con­
sequences of chronic alcoholism, alcoholic
dementia, or KS. 
Chronic Alcoholism. Samson and col­
leagues (1986) used PET to study cerebral
glucose metabolism in six chronic alco­
holics without cognitive dysfunction. The
most characteristic finding in these patients
was reduced regional glucose metabolism
in the mesial frontal lobe, a region near the
middle of the frontal lobe that is connected 
with structures of the limbic system and
diencephalon and may be involved in mem­
ory functions. Other studies found similar
results, as well as reduced metabolism in
the cerebellum (a structure at the base of
the brain involved in the control of move­
ment and speech), in alcoholic patients
exhibiting some neuropsychological im­
pairments (Gilman et al. 1990). Still other
researchers reported diminished metabolic
rates throughout the cortex of alcoholic
patients (Wik et al. 1988; Sachs et al. 1987).
Thus, it appears that alcoholic patients both
with and without cognitive impairment may
show metabolic deficits in several brain re­
gions, especially in the mesial frontal lobe.
Rarely, however, has research examined the
relationship between the observed metabolic
changes and specific cognitive impairments.
For example, Adams and colleagues (1993)
correlated reduced glucose metabolism in
the mesial frontal lobe with the patients’
performance on tests measuring cognitive
functions (e.g., abstract thinking) that have
been associated with this region. 
Korsakoff’s Syndrome. A few studies have 
examined glucose metabolism and RCBF
in KS patients. Using PET, Kessler and
colleagues (1984) noted a global reduction
of glucose metabolism in these patients. The 
specific metabolic patterns varied among
the patients: While some had particularly
low metabolism in the frontal lobe but 
elevated metabolism in subcortical struc­
tures (e.g., the basal ganglia and the thala­
mus), others showed the opposite pattern.
The interpretation of these findings was
limited, however, because the study did not
include alcoholics without KS for compari­
son. Other researchers found that KS pa­
tients had reduced glucose metabolism in the
frontal and parietal lobes and in the cingu­
late gyrus (i.e., a part of the limbic system
that, among other functions, has been
associated with performance on some
memory tasks) compared with alcoholic
control subjects (Paller et al. 1993).
The reduced metabolism and, thus, the
reduced nerve cell activity in the cortex
could have two causes. First, it could be
the direct result of alcohol­induced damage
to nerve cells in the cortex. Alternatively, it
could indirectly result from damage to cells
in the diencephalon, which are extensively
connected with cells in the cortex. Both 
diencephalic and cortical damage and dys­
function have been observed in KS pa­
tients, suggesting that the memory deficits
of KS patients, which often have been attri­
buted to damage to diencephalic structures,
also may be related to functional abnormal­
ities in the cortex. For example, a SPECT
study of RCBF in KS patients found a
correlation between impaired performance
on memory and orientation tests and dimin­
ished RCBF in the frontal lobes (Hunter
et al. 1989). 
CONCLUSIONS 
Imaging technologies, especially new
functional imaging methods, have signifi­
cantly enhanced our understanding of the
pathophysiological processes in the brain
that lead to or result from various types of
neurodegenerative diseases and other
causes of dementia as well as the normal 
aging process. These studies have helped
define different types of dementia (e.g.,
AD versus IVD) and predict their clinical
course. Based on imaging studies, we now
know, for example, that the size of the
hippocampus can predict subsequent cog­
nitive decline in aging subjects (deLeon et
al. 1993) and that the extent of RCBF re­
duction in the temporal lobe indicates the
rate of cognitive decline in AD patients
(Wolfe et al. 1995). Other studies have
identified people at risk for AD based on
reduced glucose metabolism in the parietal
cortex, and long­term studies of these peo­
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ple may allow researchers to monitor treat­
ment responses in the earliest stages of the
disease (Small et al. 1995).
Functional imaging technologies such
as SPECT and PET also potentially are
useful for investigating some of the causes
and consequences of alcoholism. For ex­
ample, imaging studies may help to disen­
tangle the effects of aging from the effects
of alcoholism. Studies demonstrating simi­
lar changes in brain metabolism among
older people and in alcoholics indicate that
chronic alcohol consumption may induce
or accelerate aging processes in the brain.
This hypothesis is supported by imaging
analyses showing that the volume of the
hippocampus decreases both in chronic
alcoholics and in the course of aging; this
effect is more pronounced in older alco­
holics than in younger alcoholics
(Sullivan et al. 1995).
Imaging studies also may help re­
searchers relate physiological changes in
alcoholics to observed cognitive deficits.
In particular, the development of new
SPECT and PET radiotracers should per­
mit the evaluation of a number of neuro­
transmitter systems and the relationship
between physiological changes in these
systems and specific cognitive deficits.
Imaging studies also may be useful for
defining specific alcohol­related neuro­
behavioral syndromes (e.g., chronic al­
coholism without dementia, alcoholic
dementia, and KS) in the same way they
have helped define different types of de­
mentia. Finally, imaging might be used to
identify alcoholics likely to develop demen­
tia as well as to predict the progression of
cognitive changes. To realize their potential
and to determine the relationships between
functional changes, clinical presentation,
and specific cognitive impairments, how­
ever, future imaging studies must clearly
characterize the neurobehavioral status of 
their subjects and include appropriate
control groups. 
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